Immuno-Oncology: Emerging Targets and Combination Therapies

Host immunity recognizes and eliminates most early tumor cells, yet immunological checkpoints, exemplified by CTLA-4, PD-1, and PD-L1, pose a significant obstacle to effective antitumor immune responses. T-lymphocyte co-inhibitory pathways influence intensity, inflammation and duration of antitumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Marshall, Henry T., Djamgoz, Mustafa B. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6115503/
https://www.ncbi.nlm.nih.gov/pubmed/30191140
http://dx.doi.org/10.3389/fonc.2018.00315

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6115503/
https://www.ncbi.nlm.nih.gov/pubmed/30191140
http://dx.doi.org/10.3389/fonc.2018.00315

Ejemplares similares